# Study of Infigratinib in Children With Achondroplasia

> **NCT04265651** · PHASE2 · COMPLETED · sponsor: **QED Therapeutics, a BridgeBio company** · enrollment: 84 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** Infigratinib 0.016 mg/kg
- **DRUG:** Infigratinib 0.032 mg/kg
- **DRUG:** Infigratinib 0.064 mg/kg
- **DRUG:** Infigratinib 0.128 mg/kg
- **DRUG:** Infigratinib 0.25 mg/kg

## Key facts

- **NCT ID:** NCT04265651
- **Lead sponsor:** QED Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-10
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265651, "Study of Infigratinib in Children With Achondroplasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04265651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*